Healthcare Decision: What Happens Now?

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events among those treated with zanubrutinib compared with ibrutinib.

George Jones of UpScript Health discusses telemedicine's evolution from basic e-prescribing to real-time video consultations, expanding treatment beyond primary care.

Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.

The annual wellness visit is beneficial for patients, providers, and payers with an emphasis on preventive care for early intervention.

Chronic inflammatory demyelinating polyneuropathy (CIPD) can have a substantial impact on patients everyday life and, consequently, put added stress on health care systems.

The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.